hu5f9-g4
mAbexperimental
Clinical trial activity
8 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2014 (NCT02216409)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Hematologic Neoplasms · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1/Phase 2
Mechanism of action
- Leukocyte surface antigen CD47INHIBITOR
CD47 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- hu5f9-g4
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03922477 | Phase 1 | Aug 30, 2019 | Roche |
| NCT03869190 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2019 | Astellas, Forty Seven, Inc., Roche, Seattle Genetics, Tesaro |
| NCT03558139 | Phase 1 | May 24, 2018 | Forty Seven, Inc., Merck KGaA |
| NCT03248479 | Phase 1 | Sep 12, 2017 | Forty Seven, Inc. |
| NCT02953782 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2016 | Forty Seven, Inc. |
| NCT02953509 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2016 | Forty Seven, Inc. |
| NCT02678338 | Phase 1 | Nov 1, 2015 | Forty Seven, Inc., University of Oxford |
| NCT02216409 | Phase 1 | Aug 1, 2014 | Forty Seven, Inc. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Forty Seven, Inc. | For profit | 7 | 6 | 2 | 2014 |
| Roche | For profit | 2 | 2 | 2 | 2019 |
| Astellas | For profit | 1 | 0 | 1 | 2019 |
| Merck KGaA | For profit | 1 | 0 | 1 | 2018 |
| Seattle Genetics | For profit | 1 | 0 | 1 | 2019 |
| Tesaro | For profit | 1 | 0 | 1 | 2019 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2015 |
7 organizations
Page 1 / 1